Cargando…

Integration of the cancer-related inflammatory response as a stratifying biomarker of survival in hepatocellular carcinoma treated with sorafenib

BACKGROUND AND AIMS: Response to sorafenib is highly variable in hepatocellular carcinoma (HCC). Baseline inflammatory parameters and treatment toxicities may improve survival prediction in patients on sorafenib therapy. RESULTS: 442 patients with advanced stage HCC on sorafenib were recruited (foll...

Descripción completa

Detalles Bibliográficos
Autores principales:	Howell, Jessica A., Pinato, David J., Ramaswami, Ramya, Arizumi, Tadaaki, Ferrari, Carlotta, Gibbin, Antonello, Burlone, Michela E., Guaschino, Giulia, Toniutto, Pierluigi, Black, James, Sellers, Laura, Kudo, Masatoshi, Pirisi, Mario, Sharma, Rohini
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5482646/ https://www.ncbi.nlm.nih.gov/pubmed/28212535 http://dx.doi.org/10.18632/oncotarget.15322

Ejemplares similares

Prognostic sub-classification of intermediate-stage hepatocellular carcinoma: a multicenter cohort study with propensity score analysis
por: Ramaswami, Ramya, et al.
Publicado: (2016)

Impact of age on sorafenib outcomes in hepatocellular carcinoma: an international cohort study
por: Hajiev, Saur, et al.
Publicado: (2020)

Correction: Impact of age on sorafenib outcomes in hepatocellular carcinoma: an international cohort study
por: Hajiev, Saur, et al.
Publicado: (2021)

Combined sequential use of HAP and ART scores to predict survival outcome and treatment failure following chemoembolization in hepatocellular carcinoma: a multi-center comparative study
por: Pinato, David J., et al.
Publicado: (2016)

Gankyrin induces STAT3 activation in tumor microenvironment and sorafenib resistance in hepatocellular carcinoma
por: Sakurai, Toshiharu, et al.
Publicado: (2017)

Comparison of systems for assessment of post-therapeutic response to sorafenib for hepatocellular carcinoma
por: Arizumi, Tadaaki, et al.
Publicado: (2014)

Pancreatobiliary Reflux Resulting in Pancreatic Ascites and Choleperitoneum after Gallbladder Perforation
por: Rapetti, Rachele, et al.
Publicado: (2008)

Cold-inducible RNA-binding protein promotes the development of liver cancer
por: Sakurai, Toshiharu, et al.
Publicado: (2015)

Antiviral treatment in patients with hepatitis C virus-related cirrhosis awaiting liver transplantation
por: Toniutto, Pierluigi, et al.
Publicado: (2008)

The role of LDH serum levels in predicting global outcome in HCC patients treated with sorafenib: implications for clinical management
por: Faloppi, Luca, et al.
Publicado: (2014)

Special Issue “New Therapies of Liver Diseases”
por: Toniutto, Pierluigi
Publicado: (2022)

Cardiac dysfunction as an early predictor of portal hypertension in chronic hepatitis C
por: Marconi, Cecilia, et al.
Publicado: (2017)

17β-Oestradiol Protects from Hepatitis C Virus Infection through Induction of Type I Interferon
por: Barbaglia, Matteo Nazzareno, et al.
Publicado: (2022)

Sorafenib-resistant hepatocellular carcinoma stratified by phosphorylated ERK activates PD-1 immune checkpoint
por: Chen, Jiang, et al.
Publicado: (2016)

Integrated analysis of multiple receptor tyrosine kinases identifies Axl as a therapeutic target and mediator of resistance to sorafenib in hepatocellular carcinoma
por: Pinato, David J., et al.
Publicado: (2019)

Direct antivirals and cognitive impairment in hepatitis C: a clinical-neurophysiologic study
por: Vaghi, Gloria, et al.
Publicado: (2020)

Periostin Circulating Levels and Genetic Variants in Patients with Non-Alcoholic Fatty Liver Disease
por: Smirne, Carlo, et al.
Publicado: (2020)

Unique Association between Global DNA Hypomethylation and Chromosomal Alterations in Human Hepatocellular Carcinoma
por: Nishida, Naoshi, et al.
Publicado: (2013)

Liver Stiffness, Not Fat Liver Content, Predicts the Length of QTc Interval in Patients with Chronic Liver Disease
por: Bellan, Mattia, et al.
Publicado: (2019)

Genetic Polymorphisms of Vitamin D Pathway Predict Antiviral Treatment Outcome in Slow Responder Naïve Patients with Chronic Hepatitis C
por: Falleti, Edmondo, et al.
Publicado: (2013)

Red Cell Distribution Width and Platelet Count as Biomarkers of Pulmonary Arterial Hypertension in Patients with Connective Tissue Disorders
por: Bellan, Mattia, et al.
Publicado: (2019)

17,β‐estradiol inhibits hepatitis C virus mainly by interference with the release phase of its life cycle
por: Magri, Andrea, et al.
Publicado: (2016)

Management of Hepatocellular Cancer in the time of SARS‐CoV‐2
por: Sharma, Rohini, et al.
Publicado: (2020)

Impact of NAFLD on clinical outcomes in hepatocellular carcinoma treated with sorafenib: an international cohort study
por: Howell, Jessica, et al.
Publicado: (2022)

Liver Transplantation in Patients with Hepatocellular Carcinoma beyond the Milan Criteria: A Comprehensive Review
por: Toniutto, Pierluigi, et al.
Publicado: (2021)

Clinical update on the efficacy of anti-SARS-CoV-2 mRNA vaccines in patients on the waiting list for liver transplantation and in liver transplant recipients
por: Toniutto, Pierluigi, et al.
Publicado: (2021)

Drug–Drug Interactions in Italian Patients with Chronic Hepatitis C Treated with Pangenotypic Direct Acting Agents: Insights from a Real-World Study
por: Mangia, Alessandra, et al.
Publicado: (2021)

Cost-effectiveness analysis of lenvatinib treatment for patients with unresectable hepatocellular carcinoma (uHCC) compared with sorafenib in Japan
por: Kobayashi, Masahiro, et al.
Publicado: (2019)

Safety and efficacy of sorafenib in Japanese patients with hepatocellular carcinoma in clinical practice: a subgroup analysis of GIDEON
por: Kudo, Masatoshi, et al.
Publicado: (2016)

Mechanisms of Resistance to Immunotherapy in Hepatocellular Carcinoma
por: Manfredi, Giulia Francesca, et al.
Publicado: (2023)

Atezolizumab plus Bevacizumab versus Sorafenib for Unresectable Hepatocellular Carcinoma: Results from Older Adults Enrolled in the IMbrave150 Randomized Clinical Trial
por: Li, Daneng, et al.
Publicado: (2022)

Implementing Risk-Stratified Breast Screening in England: An Agenda Setting Meeting
por: McWilliams, Lorna, et al.
Publicado: (2022)

Preliminary qualification of a novel, hypoxic-based radiologic signature for trans-arterial chemoembolization in hepatocellular carcinoma
por: Pinato, David J., et al.
Publicado: (2018)

Sorafenib plus hepatic arterial infusion chemotherapy with cisplatin versus sorafenib for advanced hepatocellular carcinoma: randomized phase II trial
por: Ikeda, M., et al.
Publicado: (2016)

Inference of epidemiological parameters from household stratified data
por: Walker, James N., et al.
Publicado: (2017)

Stratifying the stratifiers of triple negative breast cancer
por: Wang, Dong-Yu, et al.
Publicado: (2020)

Interplay of PNPLA3 and HSD17B13 Variants in Modulating the Risk of Hepatocellular Carcinoma among Hepatitis C Patients
por: De Benedittis, Carla, et al.
Publicado: (2020)

Improvement of insulin sensitivity in diabetic and non diabetic patients with chronic hepatitis C treated with direct antiviral agents
por: Gualerzi, Alessandro, et al.
Publicado: (2018)

Pharmacokinetic Interaction between Sorafenib and Atorvastatin, and Sorafenib and Metformin in Rats
por: Karbownik, Agnieszka, et al.
Publicado: (2020)

Programmed cell death ligands expression in phaeochromocytomas and paragangliomas: Relationship with the hypoxic response, immune evasion and malignant behavior
por: Pinato, David J., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_9u2c4vl44ufscbju52env9jpis